Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 29, 2015
- Accepted in final form November 10, 2015
- First Published January 27, 2016.
Author Disclosures
- Nicholas Schwab, PhD*,
- Tilman Schneider-Hohendorf, PhD*,
- Béatrice Pignolet, PhD,
- Johanna Breuer, PhD,
- Catharina C. Gross, PhD,
- Kerstin Göbel, MD,
- David Brassat, MD, PhD and
- Heinz Wiendl, MD
- Nicholas Schwab, PhD*,
NONE
NONE
(1) Biogen, travel expenses, (2) Novartis, speaking honoraria
NONE
(1) Usage of L-selectin as predictive marker for PML.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) DFG CRC128 B1, starting 2012 (2) University M?nster, IMF, starting 2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tilman Schneider-Hohendorf, PhD*,
NONE
NONE
Biogen, travel support for scientific conference attendance.
NONE
(1) usage of L-selectin as predictive marker for the risk to develop PML (pantent nr.: EP 11 185 439 & EP 12 158 369)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Béatrice Pignolet, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Johanna Breuer, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Catharina C. Gross, PhD,
NONE
NONE
I received speaker honoraria and travel expenses for attending meetings from Genzyme, Novartis Pharma GmbH, and Bayer Health Care.
Frontiers in Immunology, Review Editor, Since 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research Foundation (DFG), GR3946/2-1, 01/2013-12/2015
Innovative Medical Science Grant (IMF-grant) of the medical faculty of the University of M?nster, KL111421, 07/2014-06/2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kerstin Göbel, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Brassat, MD, PhD and
Chugai pharma
NONE
Biogen idec, sanofi genzyme, teva, merck serono, bayer, almirall
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
French Ministry of Health 2007 PI, French multiple sclerosis Society 2005, 2006, 2007, 2008, European Union FP7 marie curie Action, 2008
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD
(1) Bayer Healthcare (2) Biogen Idec (3) Sanofi- Genzyme (4) Merck Serono (5) Novartis (6) Roche (7) Teva
NONE
(1) Bayer Vital GmbH (2) Bayer Schering AG (3) Biogen (4) CSL Behring (5) EMD Serono (6) Fresenius Medical Care (7) Sanofi - Genzyme (8) Merck Serono (9) Omniamed (10) Novartis (11) Teva
(1) Journal of Clinical Practice, Editorial Board member, since 2006 (2) Journal of Neuroinflammation, Editorial Board member, since 2007 (3) PLOS ONE, Editorial board member, since 2013
NONE
NONE
NONE
(1) Biogen Idec (2) Merck Serono (3) Novartis (4) Omniamed (5) Roche (6) Sanofi-Genzyme.
NONE
NONE
NONE
(1) Bayer Healthcare (2) Bayer Vital (3) Biogen Idec (4) Merck Serono (5) Novartis (6) Sanofi ? Genzyme (7) Sanofi US (8) TEVA Pharma
(1) German Ministry for Education and Research (BMBF), BD120300, Principal Investigator, 2012-2015 (2) German Ministry for Education and Research (BMBF), BD604262, Principal Investigator, 2013-2016 (3) Deutsche Forschungsgesellschaft (DFG), WI 1722/12-1, Principal Investigator, 2012-2015 (4) Deutsche Forschungsgesellschaft (DFG), WI 1722/13-1, Principal Investigator, 2012-2015 (5) European Union, BD604219, 2013-2015 (6) Deutsche Forschungsgesellschaft (DFG), SFB 1009 TP A3, Principal Investigator, 2012-2015 (6) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP A9, Principal Investigator, 2012-2015 (7) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP B1, Principal Investigator, 2012-2015 (8) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP Z2, Principal Investigator, 2012-2015 Else Kr?ner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, Merck Serono, Novartis, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, RE Children?s Foundation. (5) Novartis (6) Sanofi Aventis NovoNordisk)
NONE
(1) Else Kr?ner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children?s Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (N.S., T.S.-H., J.B., C.C.G., K.G., H.W.), University of Münster, Germany; and Pole des Neurosciences Centre Hospitalier Universitaire Toulouse (B.P., D.B.), CPTP INSERM UMR 1043 et Université de Toulouse, UPS, Toulouse, France. D.B. also represents the BioNAT Study Group.
- Correspondence to Prof. Wiendl: heinz.wiendl{at}ukmuenster.de or Dr. Schwab: nicholas.schwab{at}ukmuenster.de
Article usage
Cited By...
Letters: Rapid online correspondence
- Re:Time to audit all reported PML cases
- Nicholas Schwab, Assistant Professor, Department of Neurology, University of Muenster, Germany.nicholas.schwab@ukmuenster.de
- T. Schneider-Hohendorf; H. Wiendl;
Submitted February 22, 2016 - Time to audit all reported PML cases
- Jagannadha Avasarala, Associate Professor of Neurology, Greenville Health System & U of South Carolina School of Medicinejavasarala@ghs.org
Submitted February 16, 2016
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.